511 related articles for article (PubMed ID: 23828371)
1. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
[TBL] [Abstract][Full Text] [Related]
2. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
[TBL] [Abstract][Full Text] [Related]
4. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
7. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses.
Valentin L; Jurkovic D; Van Calster B; Testa A; Van Holsbeke C; Bourne T; Vergote I; Van Huffel S; Timmerman D
Ultrasound Obstet Gynecol; 2009 Sep; 34(3):345-54. PubMed ID: 19585547
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
[TBL] [Abstract][Full Text] [Related]
9. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
Van Calster B; Timmerman D; Bourne T; Testa AC; Van Holsbeke C; Domali E; Jurkovic D; Neven P; Van Huffel S; Valentin L
J Natl Cancer Inst; 2007 Nov; 99(22):1706-14. PubMed ID: 18000221
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
11. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
12. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help.
Valentin L; Ameye L; Savelli L; Fruscio R; Leone FP; Czekierdowski A; Lissoni AA; Fischerova D; Guerriero S; Van Holsbeke C; Van Huffel S; Timmerman D
Ultrasound Obstet Gynecol; 2011 Oct; 38(4):456-65. PubMed ID: 21520475
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings.
Wilailak S; Chan KK; Chen CA; Nam JH; Ochiai K; Aw TC; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Charakorn C; Sumpaico WW
J Gynecol Oncol; 2015 Jan; 26(1):46-53. PubMed ID: 25310857
[TBL] [Abstract][Full Text] [Related]
14. RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study.
Liest AL; Omran AS; Mikiver R; Rosenberg P; Uppugunduri S
Acta Obstet Gynecol Scand; 2019 Jan; 98(1):24-33. PubMed ID: 30216407
[TBL] [Abstract][Full Text] [Related]
15. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
17. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
19. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
[TBL] [Abstract][Full Text] [Related]
20. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
Holcomb K; Vucetic Z; Miller MC; Knapp RC
Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]